UBS Says Market May View Apollo Global Management's (APO) Repurchase Plan Positively - Reiterates Buy

Go back to UBS Says Market May View Apollo Global Management's (APO) Repurchase Plan Positively - Reiterates Buy

Piper Jaffray Remains Bullish as Apollo Global Management (APO) Institutes $250M Buyback Program

February 4, 2016 9:53 AM EST

Piper Jaffray maintained an Overweight rating on Apollo Global Management (NYSE: APO), and cut the price target to $26.00 (from $32.00), following the company's 4Q earnings report. APO instituted a $250M buyback program. Importantly, the buybacks will be funded from balance sheet resources and doesn't represent a change... More

Apollo Global Management (APO) Declares $0.28 Quarterly Dividend; 8.7% Yield

February 3, 2016 7:25 AM EST

Apollo Global Management (NYSE: APO) declared a quarterly dividend of $0.28 per share, or $1.12 annualized.

The dividend will be payable on February 29, 2016, to stockholders of record on February 19, 2016, with an ex-dividend date of February 17, 2016.

The annual yield on the dividend is 8.7... More

Apollo Global Management (APO) Misses Q4 EPS by 18c; Approves $250M Buyback Plan

February 3, 2016 7:24 AM EST

Apollo Global Management (NYSE: APO) reported Q4 EPS of $0.08, $0.18 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $222.82 million versus the consensus estimate of $282.87 million.

AUM:

Total Assets Under Management (gAUMh) of $170.1 billionFee-Generating AUM (gFGAUMh) of... More

Trading Radar for 2/3: GM (GM), GoPro (GPRO), International Paper (IP), MetLife (MET) Report

February 2, 2016 3:17 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
7:00am EST

MBA Mortgage Index - no Street consensus

8:15am EST

ADP Employment Change - Street sees 190k

Earnings:

ABB Ltd. (NYSE: ABB) - consensus EPS $0.21
Acorn International (NYSE: ATV) - no Street consensus
Agilysys, Inc. (Nasdaq: AGYS) - consensus loss $0.09
Alexion Pharma (Nasdaq: ALXN) - consensus... More